Pfizer (PFE) has filed a new clinical trial this week for its drug candidate PF-00345439. We believe a long position in DRRX or PTIE may be warranted based on this development as outlined herein.
A quick check of previous clinical trials shows that this internal identifier refers to Remoxy, the abuse-resistant oxycodone formulation developed originally by Durect Corporation (DRRX), licensed to Pain Therapeutics (PTIE) and partnered to PFE ((see image below).
430 people received this article by email alert
Add your email to get alerts on PTIE too:
Get email alerts on PTIE »